The United States Food and Drug Administration has officially granted marketing authorization to Eli Lilly and Company for Onswik, chemically…
Read More
New Stanford Medicine Study Reveals Protein-Targeting Treatment Restores Lost Knee Cartilage and Prevents Osteoarthritis in Preclinical Trials
A groundbreaking scientific discovery led by researchers at Stanford Medicine has demonstrated that targeting a specific protein linked to the…
Read More
Navigating the Oncology Enrollment Funnel: Why Cancer Clinical Trials Face Protracted Timelines and High Screen Failures
The modern landscape of oncology drug development is characterized by profound scientific breakthroughs, yet it remains perpetually bottlenecked by an…
Read More
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Recent findings presented at the 26th International AIDS Conference have underscored a significant advancement in HIV treatment, with an investigational…
Read More
Eli Lilly’s Retatrutide Demonstrates Superior Weight Loss Efficacy Amidst Elevated Side Effect Profile in Phase 3 Trials
INDIANAPOLIS, IN – Eli Lilly and Company has announced groundbreaking Phase 3 trial results for its investigational drug, retatrutide, a…
Read More
The Crucial Role of Data Reliability in Early-Phase Clinical Trials for Pharmaceutical Development
In the intricate landscape of pharmaceutical research and development, the integrity of data generated during early-phase clinical trials serves as…
Read More
Contraline Secures $92.5 Million in Series B Funding to Advance Reversible Male Contraceptive to Late-Stage Clinical Trials
Contraline, a pioneering biotechnology firm backed by Google Ventures, has successfully closed a substantial $92.5 million Series B financing round.…
Read More
Eli Lilly’s Retatrutide Demonstrates Unprecedented Weight Loss with Notable Side Effect Profile in Phase 3 Trials
Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More
Scaling GLP-1 Obesity Trials Without Losing DXA Data
The explosive growth of global obesity trials, fueled by the success of GLP-1 receptor agonist therapies, presents a critical challenge:…
Read More
Saudi Arabia Ascends as a Premier Middle Eastern Hub for Clinical Trials Fueled by Strategic Investment and Infrastructure Development
Saudi Arabia is rapidly solidifying its position as the preeminent growth market for clinical trials within the Middle East, a…
Read More
